Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376440 | 0.83 | JMJD6 (0.48) | JMJD6KDM4ECA12CA1CA2 | |
| SCHEMBL22926233 | 0.81 | JMJD6 (0.54) | JMJD6KDM4EPOLBHPGDHTT | |
| SCHEMBL13337089 | 0.80 | PIK3C3 (0.43) | HPGDESR1ALDH1A1 | |
| SCHEMBL2251313 | 0.79 | ESR1 (0.47) | JMJD6KDM4EPOLBCA12CA1 | |
| SCHEMBL15800774 | 0.78 | CYP2C9 (0.55) | JMJD6KDM4EPOLBCA12CA1 | |
| SCHEMBL10138744 | 0.78 | NTRK1 (0.48) | — | |
| SCHEMBL12984962 | 0.77 | TBXAS1 (0.47) | KDM4EPOLBTBXAS1ALDH1A1LMNA | |
| SCHEMBL6413579 | 0.77 | KDM4E (0.47) | JMJD6KDM4EPOLBHPGDTBXAS1 | |
| SCHEMBL23089629 | 0.77 | NAMPT (0.53) | PIK3CA | |
| SCHEMBL557414 | 0.76 | KDM4C (0.44) | JMJD6KDM4EPOLBCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | claimed |
| EP-4010330-B1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | HIRUNDO BIOSCIENCES (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4433477-A1 | PAD4 INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118679162-A | PAD4 inhibitors and uses thereof | 锐格药业公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009047522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | PADI4, PADI6, PADI2 | JMJD6 80/4885KDM4E 172/4885POLB 855/4885 |
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | JMJD6 3078/4885KDM4E 3990/4885POLB 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.